A Clinical Study of Cystone GNX Tablet in Urolithiasis (Kidney stones)
- Conditions
- Health Condition 1: N209- Urinary calculus, unspecified
- Registration Number
- CTRI/2017/08/009545
- Lead Sponsor
- The Himalaya Drug Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Subject with Urolithiasis as diagnosed by clinically and ultrasonographically with calculi measuring 5-10mm.
2. Subjects aged between 18-50 years of either sex.
3. Hematologic and Biochemical parameters within normal limits.
4. Willing to sign inform consent document and follow study procedures.
1.Subjects with severe obstructive uropathy,
2.Subjects with serious systemic medical disorder,
3.Subjects not to have used any drugs for at least 1 week prior to the study,
4.Subjects with a strong history of food or drug allergy,
5.Subjects not to have been on weight reducing diets within 3 months prior to the start of the study,
6.No other drugs (including aspirin) to be ingested during the course of the study,
7.Pregnant and lactating women
8.Patients unwilling to provide informed consent or abide by the requirements of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method